Total neoadjuvant therapy versus standard neoadjuvant treatment strategies for the management of locally advanced rectal cancer: network meta-analysis of randomized clinical trials

被引:20
作者
Donnelly, Mark [1 ,2 ]
Ryan, Odhran K. [1 ,2 ]
Ryan, Eanna J. [1 ]
Creavin, Ben [1 ]
O'Reilly, Mary [3 ]
McDermott, Ray [2 ,3 ]
Kennelly, Rory [1 ,4 ]
Hanly, Ann [1 ,4 ]
Martin, Sean T. [1 ,4 ]
Winter, Des C. [1 ,2 ,4 ]
机构
[1] St Vincents Univ Hosp, Dept Surg, Dublin, Ireland
[2] Univ Coll, Sch Med, Dublin, Ireland
[3] St Vincents Univ Hosp, Dept Oncol, Dublin, Ireland
[4] St Vincents Univ Hosp, Ctr Colorectal Dis, Dublin, Ireland
关键词
SHORT-COURSE RADIOTHERAPY; TOTAL MESORECTAL EXCISION; PATHOLOGICAL COMPLETE RESPONSE; PREOPERATIVE CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; OPEN-LABEL; PHASE-II; POSTOPERATIVE CHEMORADIOTHERAPY; CONCOMITANT CHEMORADIOTHERAPY; CONSOLIDATION CHEMOTHERAPY;
D O I
10.1093/bjs/znad177
中图分类号
R61 [外科手术学];
学科分类号
摘要
This study has demonstrated that total neoadjuvant therapy (TNT) has improved survival and recurrence benefits compared with current standards of care. TNT treatment strategies also improve radiological and oncological responses to treatment, and may increase the number of patients suitable for organ preservation, without negatively influencing treatment toxicity or compliance. Background This study compared the advantages and disadvantages of total neoadjuvant therapy (TNT) strategies for patients with locally advanced rectal cancer, compared with the more traditional multimodal neoadjuvant management strategies of long-course chemoradiotherapy (LCRT) or short-course radiotherapy (SCRT). Methods A systematic review and network meta-analysis of exclusively RCTs was undertaken, comparing survival, recurrence, pathological, radiological, and oncological outcomes. The last date of the search was 14 December 2022. Results In total, 15 RCTs involving 4602 patients with locally advanced rectal cancer, conducted between 2004 and 2022, were included. TNT improved overall survival compared with LCRT (HR 0.73, 95 per cent credible interval 0.60 to 0.92) and SCRT (HR 0.67, 0.47 to 0.95). TNT also improved rates of distant metastasis compared with LCRT (HR 0.81, 0.69 to 0.97). Reduced overall recurrence was observed for TNT compared with LCRT (HR 0.87, 0.76 to 0.99). TNT showed an improved pCR compared with both LCRT (risk ratio (RR) 1.60, 1.36 to 1.90) and SCRT (RR 11.32, 5.00 to 30.73). TNT also showed an improvement in cCR compared with LCRT (RR 1.68, 1.08 to 2.64). There was no difference between treatments in disease-free survival, local recurrence, R0 resection, treatment toxicity or treatment compliance. Conclusion This study provides further evidence that TNT has improved survival and recurrence benefits compared with current standards of care, and may increase the number of patients suitable for organ preservation, without negatively influencing treatment toxicity or compliance.
引用
收藏
页码:1316 / 1330
页数:15
相关论文
共 50 条
  • [21] A Meta-analysis of Total Neoadjuvant Therapies Combining Chemoradiotherapy with Induction or Consolidated Chemotherapy for Locally Advanced Rectal Cancer
    Nov, Pengkhun
    Du, Kunpeng
    Huang, Zijian
    Li, Yanyang
    Gong, Min
    Liu, Xiang
    Li, Chunhui
    Li, Lilin
    Wang, Duanyu
    Zhang, Yangfeng
    Wang, Changqian
    Li, Jiqiang
    JOURNAL OF GASTROINTESTINAL CANCER, 2023, 54 (03) : 693 - 702
  • [22] Personalized total neoadjuvant therapy versus chemotherapy during the 'wait period' versus standard chemoradiotherapy for locally advanced rectal cancer
    Bedrikovetski, Sergei
    Traeger, Luke
    Fitzsimmons, Tracy
    Perry, Joanne
    Vather, Ryash
    Moore, James W. W.
    Sammour, Tarik
    ANZ JOURNAL OF SURGERY, 2022, : 1267 - 1273
  • [23] Comparison of Standard Neoadjuvant Therapy and Total Neoadjuvant Therapy in Terms of Effectiveness in Patients Diagnosed with Locally Advanced Rectal Cancer
    Bayramgil, Ayberk
    Bilici, Ahmet
    Tatli, Ali Murat
    Kahraman, Seda
    Altintas, Yunus Emre
    Akgul, Fahri
    Aykan, Musa Baris
    Hamdard, Jamshid
    Goksu, Sema Sezgin
    Sendur, Mehmet Ali Nahit
    Selcukbiricik, Fatih
    Olmez, Omer Fatih
    MEDICINA-LITHUANIA, 2025, 61 (02):
  • [24] Total neoadjuvant therapy for the treatment of locally advanced rectal cancer: a systematic minireview
    Guida, Andrea M.
    Sensi, Bruno
    Formica, Vincenzo
    D'Angelillo, Rolando M.
    Roselli, Mario
    Blanco, Giovanna Del Vecchio
    Rossi, Piero
    Capolupo, Gabriella T.
    Caricato, Marco
    Sica, Giuseppe S.
    BIOLOGY DIRECT, 2022, 17 (01)
  • [25] Prolonged interval to surgery following neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A meta-analysis of randomized controlled trials
    Owens, P. W.
    Saeed, M.
    McCawley, N.
    Loughlin, P.
    Kearney, D. E.
    Burke, J. P.
    McNamara, D. A.
    Sahebally, S. M.
    SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND, 2024, 22 (03): : 166 - 173
  • [26] A systematic review and network meta-analysis of randomised controlled trials comparing neoadjuvant treatment strategies for stage II and III rectal cancer
    Simillis, Constantinos
    Khatri, Amulya
    Dai, Nick
    Afxentiou, Thalia
    Jephcott, Catherine
    Smith, Sarah
    Jadon, Rashmi
    Papamichael, Demetris
    Khan, Jim
    Powar, Michael P.
    Fearnhead, Nicola S.
    Wheeler, James
    Davies, Justin
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 183
  • [27] Pathological Complete Response Following Different Neoadjuvant Treatment Strategies for Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis
    Hoendervangers, S.
    Burbach, J. P. M.
    Lacle, M. M.
    Koopman, M.
    van Grevenstein, W. M. U.
    Intven, M. P. W.
    Verkooijen, H. M.
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (11) : 4319 - 4336
  • [28] Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis Oxaliplatin in neoadjuvant treatment for rectal cancer
    De Felice, Francesca
    Benevento, Ilaria
    Magnante, Anna Lisa
    Musio, Daniela
    Bulzonetti, Nadia
    Caiazzo, Rossella
    Tombolini, Vincenzo
    BMC CANCER, 2017, 17
  • [29] Total neoadjuvant therapy approach for the treatment of locally advanced rectal cancer. Where do we stand?
    Romero Zoghbi, Sigfredo Elias
    Martin, Margarita Martin
    Garcia, Juan Carlos
    Valero, Mireia
    Rincon, Diego
    Pena Huertas, Marina
    Fusco, Juan Pablo
    Lopez, Escarlata
    Zafra, Juan
    Fernandez Luengas, David
    Campos, Fernando Lopez
    Counago, Felipe
    ONCOLOGY, 2024, 102 (07) : 646 - 657